Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
REGULATORY
R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
“The pharmaceutical industry should not be the only loser. Don’t hinder innovation.” This was a mantra carried by the Ministry of Health, Labor and Welfare (MHLW) and Liberal Democratic Party (LDP) lawmakers with a special interest in health issues throughout…
To read the full story
Related Article
- MHLW Set to Defend “High-Level Investment” Credits for Key R&D Tax Break System in FY2017 Reform
August 22, 2016
- JPMA Sacks Hasegawa as Vice President after Business Improvement Order
July 3, 2015
- R&D Tax Credit Overhaul Likely in FY2017, but In a Way to Spur Investments: LDP’s Goto
February 4, 2015
- R&D Tax Credit Revamp (1): New Scheme for Open Innovation Research Significant in 3 Ways
January 20, 2015
REGULATORY
- MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
- Japan Panel to Review Kyowa Kirin’s Libmeldy for Approval on Nov. 9
November 4, 2026
- PMDA Sets Out AI Principles for Regulatory Activities, Stresses Human Oversight
November 4, 2026
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
- Japan’s Healthcare Spending Hits Record 48.8 Trillion Yen in FY2024
November 2, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…